Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib in HER2-positive digestive cancer
ChiCTR2100050661Phase 2Recruiting
- Sponsor
- Affiliated Hospital of Nantong University
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib in gastrointestinal cancer, sponsored by Affiliated Hospital of Nantong University. Primary endpoint: progression-free survival. Started Sep 2021; status: recruiting.
02
Drugs
pyrotinib
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on ChiCTR2100050661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050661.